Payson-based wellness company Life is Chill is working to break the stigma around cannabis one educational session at a time. Striving to become the leading provider of innovative, precision-dosed cannabis products, Life Is Chill offers evidence-based education on THC, CBD and other cannabinoids. Their goal is to empower individuals to understand better the potential benefits and considerations for enhancing their everyday quality of life with cannabis.

With the legalization of nonprescribed cannabis in several states, hundreds of companies across the United States produce edibles, concentrates, flowers, drinks and topicals. Life is Chill takes a different approach, setting itself apart through scientific innovation and precision in its signature line of products, all for the well-being of its customers.

“Our focus is more on the medical side,” Life is Chill Co-Founder Star Simmons said. “It is really about helping people.”

Sold throughout the state of Arizona, Life is Chill is approaching cannabis scientifically, advocating for education and transparency. The Chill Pill is a THC, precision-dosed soft gel with negligible sugar, making it ideal for those with diabetes or other dietary restrictions. Chill Pills are odorless, dye-free and some of the pills are vegan-friendly, and precision-dosed soft gels designed for discretion and consistency. With a rapid-uptake formulation, the active ingredients enter the bloodstream more quickly than with traditional edibles. This approach prioritizes purity and quality, with every batch rigorously tested to ensure consistent, reliable performance. The Chill Pill line offers a range of products designed to meet different preferences and dosing needs. For those seeking a lighter option, Life Is Chill offers 5mg THC soft gels that provide a gentle introduction or lower-dose experience. The 10mg THC products include Daytime, Flextime, Nighttime and Resintime, each tailored for different moments throughout the day. For a balanced profile, the Lifetime formula combines 10mg THC with 10mg CBD. Customers with a state-issued medical card can also purchase the Daytime, Nighttime and RSOtime soft gels in 25mg and 100mg doses. 

Unlike brands that emphasize variety alone, Life Is Chill focuses on premium, carefully crafted products and consumer education, aiming to deliver a trusted and positive cannabis experience.

“The difference between what we’re doing compared to the other brands out there is that we are precision-dosed,” Simmons said. “We have a two-system testing process, and therefore our per serving capsules are very accurate each time, opposed to some of the other edibles on the market.”

“Life Is Chill is more than a brand, it’s a lifestyle,” Simmons says. The company is dedicated to educating the senior communities in Arizona about cannabinoids and their potential role in wellness. A key focus is reaching older adults, many of whom grew up with stigmas around cannabis. By breaking down misconceptions and providing clear, accessible education, Life Is Chill is creating space for informed conversations.

The elder education team is led by Dr. Dana Lillestol, PhD, senior education advisor at Life Is Chill. She travels across the state, developing presentations for Arizona’s aging population, providing education on the wide range of cannabinoids. Her work helps individuals better understand the differences between these compounds and make informed choices that support overall wellness and quality of life. In addition, the team organizes guided dispensary tours for seniors, offering them the opportunity to explore products on the market, learn directly from budtenders, and gain confidence in navigating the retail environment.

Pharmaceutical companies have recently shifted their tone when it comes to cannabis, CBD and similar products. For years, many were opposed to legalization. However, in the past decade, big names in the industry have begun actively developing and investing in cannabinoid-based drugs. In 2021, Pfizer signed an agreement with Arena Pharmaceuticals, a biotech company creating cannabinoid-type therapeutics, for a total equity value of around $6.7 billion.

“We anticipate that, at some point, cannabis will receive federal approval in the United States,” Simmons said. “When that happens, it’s likely that pharmaceutical companies will enter the space through acquisitions as a way to bring cannabis under their umbrella. Our strategy is to position Life Is Chill in a way that aligns with that future landscape.”

Learn more about Life is Chill at lifeischill.com and Lifeischilleducation.com